GlassScriptPhysician profile
Peyton P Berookim
NPI 1770773830
$68,477.24
in general payments reported to CMS, 2019-2025
55 companies · $8,826 in 2025
The $8,826 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $16K · 2021: $7,925 · 2022: $2,029 · 2023: $9,914 · 2024: $11K · 2025: $8,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $8,517 · Education: $144 · Travel and Lodging: $44.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,900.00 |
| Food and Beverage | $8,517.17 |
| Education | $144.24 |
| Travel and Lodging | $44.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,593.70 | 2019-2025 | Viberzi, Linzess |
| Ironwood Pharmaceuticals, INC | $14,347.97 | 2020-2025 | Linzess |
| Allergan, INC. | $14,185.15 | 2019-2020 | |
| Redhill Biopharma INC. | $5,871.11 | 2020-2024 | Talicia, Talicia, Movantik |
| Concordia Pharmaceuticals INC. | $4,270.25 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,131.31 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $1,113.71 | 2019-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $971.69 | 2019-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $915.18 | 2019-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $715.54 | 2019-2025 | Rebyota, Clenpiq |
| Ardelyx, INC. | $550.39 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $445.40 | 2021-2025 | Tremfya, Stelara |
| Mannkind Corporation | $443.23 | 2019-2025 | |
| Genzyme Corporation | $433.02 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $417.97 | 2021-2023 | Zeposia |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $372.73 | 2022-2025 | Dupixent |
| Amgen INC. | $349.49 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $346.66 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $273.12 | 2019-2024 | Delstrigo, Pifeltro, Dificid |
| Madrigal Pharmaceuticals | $238.00 | 2025 | Rezdiffra |
| Romark Laboratories, Lc | $209.57 | 2019-2020 | |
| Shire North American Group INC | $200.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $173.66 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $162.15 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $156.10 | 2020-2024 | Xarelto |
| Glaxosmithkline, LLC. | $151.44 | 2019-2024 | Arexvy, Shingrix |
| Exact Sciences Corporation | $136.13 | 2023-2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $133.41 | 2023-2024 | Apretude |
| Novartis Pharmaceuticals Corporation | $112.81 | 2022-2025 | |
| Bausch Health US, LLC | $106.15 | 2022-2025 | Wellbutrin |
| Gilead Sciences, INC. | $100.79 | 2019-2023 | |
| Boston Scientific Corporation | $86.47 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.57 | 2021-2025 | Tradjenta, Jardiance, Synjardy |
| Heartflow, INC. | $69.42 | 2022-2025 | Ffrct |
| Biohaven Pharmaceuticals, INC. | $59.63 | 2021 | |
| Eisai INC. | $56.85 | 2021-2024 | |
| Esperion Therapeutics, INC. | $56.71 | 2021-2025 | Nexletol |
| Aimmune Therapeutics, INC. | $48.76 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $41.40 | 2023 | Breztri, Farxiga |
| Genentech USA, INC. | $38.35 | 2019-2021 | |
| Celgene Corporation | $33.51 | 2021-2023 | Zeposia |
| Medtronic, INC. | $27.52 | 2021-2023 | Gi Genius |
| Braintree Laboratories, INC. | $25.78 | 2025 | Suflave |
| Alnylam Pharmaceuticals INC. | $22.41 | 2024 | Amvuttra |
| Ibsa Pharma INC. | $21.29 | 2025 | Flector, Licart, Tirosint |
| Shield Therapeutics INC | $20.81 | 2023 | Accrufer |
| Ultragenyx Pharmaceutical INC. | $19.93 | 2022 | |
| Vertical Pharmaceuticals, LLC | $19.74 | 2019 | |
| Seqirus USA INC | $19.36 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.21 | 2019 | |
| Amarin Pharma, INC. | $17.47 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.44 | 2025 | Suflave |
| Pfizer INC. | $16.22 | 2019 | |
| Novo Nordisk INC | $15.62 | 2025 | Wegovy |
| Lucid Diagnostics INC. | $14.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyton Berookim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.